Statins are a widely used class of medications that lower cholesterol levels in patients with hyperlipidemia. Recent evidence suggests that statins can also reduce the risk for cerebrovascular and cardiovascular events and may be helpful in diseases of the central nervous system, including ischemic stroke, Alzheimer disease, and multiple sclerosis. Growing evidence suggests that statin drugs may also protect against worsening of OAG, one of the most common causes of blindness worldwide. Basic scientists have identified several mechanisms by which statins may protect against OAG progression-for example, by improving blood flow to the optic nerve as a result of upregulating endothelial nitric oxide synthase, and by enhancing aqueous outflow through the inhibition of Rho kinase activity. Several cohort and case-control studies have demonstrated reduced rates of OAG or disease stabilization among statin users. In preliminary analyses, we analyzed longitudinal data on a group of 524,109 enrollees, aged 60 years or older, with hyperlipidemia in a large, nationwide, managed-care network and found that persons using a statin agent had a significantly reduced risk for developing OAG and for progressing from suspected glaucoma to OAG, compared with persons who were not using statin drugs.
The aim of this R34 clinical trial planning grant is to assemble the necessary infrastructure to carry out a large, multicenter, double-masked, RCT to determine whether statins play a protective role against OAG progression in persons with mild or moderate OAG. An RCT demonstrating that statins protect against worsening of glaucoma would have important clinical implications for patient care, as it would provide an evidence basis for protecting patients from disease progression in this potentially blinding disease by using a commonly available medication for a new indication.

Public Health Relevance

This study is designed to determine whether medications that are used to treat high cholesterol called statins are protective against glaucoma progression. The discovery of a new approach to treat glaucoma, a disease that causes loss of peripheral vision and blindness, would substantially impact human health through reducing the burden of visual disability in a world where more than 60 million individuals are now blind from glaucoma.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Planning Grant (R34)
Project #
1R34EY022399-01A1
Application #
8445488
Study Section
Special Emphasis Panel (ZEY1-VSN (01))
Program Officer
Schron, Eleanor
Project Start
2012-12-01
Project End
2014-11-30
Budget Start
2012-12-01
Budget End
2014-11-30
Support Year
1
Fiscal Year
2013
Total Cost
$233,250
Indirect Cost
$83,250
Name
University of Michigan Ann Arbor
Department
Ophthalmology
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Musch, David C; Gillespie, Brenda W; Palmberg, Paul F et al. (2014) Visual field improvement in the collaborative initial glaucoma treatment study. Am J Ophthalmol 158:96-104.e2